Researchers analyzing human liver tissue from pancreatic cancer patients, alongside mouse models, report that hepatocytes supply the amino acid serine to metastasizing pancreatic cancer cells, supporting their growth in the liver. The work, which included tissue from the University of Nebraska Medical Center's Rapid Autopsy Program, used immunohistochemistry to examine markers including PHGDH, albumin, CK19, Ki67 and FOXO3A in liver samples.
nature.com
· 2026-09-23
Nature has published an author correction to a 2017 paper on genomic deletion of malic enzyme 2 (ME2) in pancreatic cancer, fixing several figure mistakes made during assembly. These include a duplicated AMPKα immunoblot image, an incorrect β-actin loading-control blot, and a mislabelled timepoint in bioluminescence imaging data.
nature.com
· 2026-09-17
Researchers combined single-cell RNA sequencing from human and mouse pancreatic tumours with protein localization databases, CRISPR dependency screens and functional annotation to identify tumour-secreted genes that shape cancer cell diversity and suppress immune responses. The filtering pipeline pinpointed a group of serpin family proteins acting through myeloid cells as key drivers of this immune evasion process. The work narrows a large pool of candidate genes down to those most likely to influence how pancreatic tumours interact with surrounding immune cells.
nature.com
· 2026-09-09
Researchers at the University of Minnesota, led by surgeon Daniel Saltzman, have developed a therapy using genetically modified Salmonella Typhimurium bacteria to carry interleukin-2, an immune-stimulating molecule, straight into tumours. Pancreatic cancer patient John Heller received the experimental treatment after starting chemotherapy for advanced disease, illustrating an early real-world test of the approach.
nature.com
· 2026-09-09
Revolution Medicines received FDA approval this week for a pancreatic cancer pill, a milestone that comes after the company fielded acquisition interest from larger pharmaceutical firms but chose to remain independent. The decision allowed it to bring the drug through regulatory approval on its own rather than as part of a larger acquirer's pipeline.
wsj.com
· 2026-08-28
The FDA has cleared daraxonrasib, a new drug for pancreatic cancer, after a large clinical trial found patients on the treatment survived roughly twice as long as those receiving standard chemotherapy. The approval gives doctors a new option for a disease long known for poor treatment outcomes.
gizmodo.com
· 2026-08-26
The FDA has approved Rasonque (daraxonrasib), a once-daily pill designed to block multiple mutated forms of the RAS protein that drive most pancreatic adenocarcinoma tumors. It is cleared for adults with metastatic disease who have already tried one systemic treatment or cannot tolerate combination chemotherapy, and the agency says it acted ahead of its original review timeline.
fda.gov
· 2026-08-26
GoKawiil